Ignite Creation Date:
2025-12-25 @ 2:15 AM
Ignite Modification Date:
2025-12-26 @ 6:09 AM
Study NCT ID:
NCT04701060
Status:
COMPLETED
Last Update Posted:
2024-12-03
First Post:
2021-01-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-01-26
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-10-04
Completion Date Type:
ACTUAL
First Submit Date:
2021-01-04
First Submit QC Date:
None
Study First Post Date:
2021-01-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-28
Last Update Post Date:
2024-12-03
Last Update Post Date Type:
ACTUAL